GSK Ventures is the strategic venture capital arm of GSK plc, one of the world's largest pharmaceutical companies. The fund invests in emerging biotechnology and healthcare companies that align with GSK's research priorities and therapeutic areas of focus. GSK Ventures makes equity investments typically ranging from £2-25 million, partnering with innovative companies in areas including infectious diseases, oncology, immunology, and genetic medicines.
Investment Focus
Investment Thesis
Corporate venture arm of GSK plc (FTSE 100 pharma). Series A to Growth stage, typically £2m-£25m cheques. Focus: therapeutics (oncology, immunology, infectious disease), vaccines, biotech platforms, digital health/AI for drug discovery, consumer healthcare innovation. Strategic investor: portfolio companies often partner with GSK for R&D, clinical trials, or commercial licensing. Global reach from London HQ. Avoids: early pre-clinical without clear data, non-healthcare sectors.
Interested in connecting?
Visit their website or reach out directly.